Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936688088> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2936688088 endingPage "S28" @default.
- W2936688088 startingPage "S28" @default.
- W2936688088 abstract "Cutaneous T-cell lymphoma (CTCL) is characterized by resistance to apoptosis involving dysregulation of the FAS ligand (FASL) - FAS death receptor pathway. CTCL cells also exhibit constitutively activated STAT proteins, which are known to upregulate and bind DNA methyltransferases (DNMTs). We hypothesized that, like many other tumor suppressor genes, FAS and FASL expression is at least partially regulated by promoter methylation. Earlier, we showed that methotrexate (MTX), a known folate antagonist, acts as a DNA methylation inhibitor via depleting the methyl donor, S-adenosylmethionine (SAM), in CTCL cells. Pyrosequencing analysis of FAS and FASL promoters showed that MTX inhibited methylation of certain CpG sites in these genes, which resulted in increased FAS/FASL expression and subsequent apoptosis via activated caspase 8. We found that shRNA mediated genetic knockdown of DNMT -1 and -3A also resulted in upregulation of FASL mRNA and protein in CTCL cell lines. However, the reduction in FASL promoter methylation induced by MTX was generally superior to that induced by shRNA knockdown and was not improved by a combination of MTX plus knockdown. Because STAT proteins help regulate DNMTs, we also evaluated the effect of multiple JAK inhibitors (fedratinib, tofacitinib, and ruxolitinib) in CTCL cells and Sezary patient’s blood. Among these, fedratinib treatment was most effective in decreasing viability, spheroid formation, and inducing apoptosis. These responses were accompanied by decreased phosphorylation of STAT3 at tyrosine-705. Taken together, our data demonstrate that enhanced apoptosis of CTCL can be induced by MTX, DNMT knockdown and JAK inhibitors. This is consistent with a mechanistic cascade in which activated STATs enhance DNMT activities that in turn suppress the expression of apoptotic factors and promote CTCL survival. Our findings suggest a therapeutic role for MTX and JAK inhibitors in the management of CTCL." @default.
- W2936688088 created "2019-04-25" @default.
- W2936688088 creator A5028759510 @default.
- W2936688088 creator A5051459543 @default.
- W2936688088 creator A5089062097 @default.
- W2936688088 date "2019-05-01" @default.
- W2936688088 modified "2023-09-30" @default.
- W2936688088 title "160 Mechanisms governing promoter methylation and apoptosis in cutaneous T-cell lymphoma: implications for therapy with methotrexate and JAK-inhibitors" @default.
- W2936688088 doi "https://doi.org/10.1016/j.jid.2019.03.236" @default.
- W2936688088 hasPublicationYear "2019" @default.
- W2936688088 type Work @default.
- W2936688088 sameAs 2936688088 @default.
- W2936688088 citedByCount "0" @default.
- W2936688088 crossrefType "journal-article" @default.
- W2936688088 hasAuthorship W2936688088A5028759510 @default.
- W2936688088 hasAuthorship W2936688088A5051459543 @default.
- W2936688088 hasAuthorship W2936688088A5089062097 @default.
- W2936688088 hasBestOaLocation W29366880881 @default.
- W2936688088 hasConcept C104317684 @default.
- W2936688088 hasConcept C127561419 @default.
- W2936688088 hasConcept C150194340 @default.
- W2936688088 hasConcept C153911025 @default.
- W2936688088 hasConcept C173396325 @default.
- W2936688088 hasConcept C185592680 @default.
- W2936688088 hasConcept C190232843 @default.
- W2936688088 hasConcept C190283241 @default.
- W2936688088 hasConcept C190727270 @default.
- W2936688088 hasConcept C3031857 @default.
- W2936688088 hasConcept C31573885 @default.
- W2936688088 hasConcept C33288867 @default.
- W2936688088 hasConcept C502942594 @default.
- W2936688088 hasConcept C55493867 @default.
- W2936688088 hasConcept C66008609 @default.
- W2936688088 hasConcept C86803240 @default.
- W2936688088 hasConcept C91965660 @default.
- W2936688088 hasConceptScore W2936688088C104317684 @default.
- W2936688088 hasConceptScore W2936688088C127561419 @default.
- W2936688088 hasConceptScore W2936688088C150194340 @default.
- W2936688088 hasConceptScore W2936688088C153911025 @default.
- W2936688088 hasConceptScore W2936688088C173396325 @default.
- W2936688088 hasConceptScore W2936688088C185592680 @default.
- W2936688088 hasConceptScore W2936688088C190232843 @default.
- W2936688088 hasConceptScore W2936688088C190283241 @default.
- W2936688088 hasConceptScore W2936688088C190727270 @default.
- W2936688088 hasConceptScore W2936688088C3031857 @default.
- W2936688088 hasConceptScore W2936688088C31573885 @default.
- W2936688088 hasConceptScore W2936688088C33288867 @default.
- W2936688088 hasConceptScore W2936688088C502942594 @default.
- W2936688088 hasConceptScore W2936688088C55493867 @default.
- W2936688088 hasConceptScore W2936688088C66008609 @default.
- W2936688088 hasConceptScore W2936688088C86803240 @default.
- W2936688088 hasConceptScore W2936688088C91965660 @default.
- W2936688088 hasIssue "5" @default.
- W2936688088 hasLocation W29366880881 @default.
- W2936688088 hasOpenAccess W2936688088 @default.
- W2936688088 hasPrimaryLocation W29366880881 @default.
- W2936688088 hasRelatedWork W1977466383 @default.
- W2936688088 hasRelatedWork W2021117062 @default.
- W2936688088 hasRelatedWork W2136192296 @default.
- W2936688088 hasRelatedWork W2150954652 @default.
- W2936688088 hasRelatedWork W2776894334 @default.
- W2936688088 hasRelatedWork W2809302083 @default.
- W2936688088 hasRelatedWork W2888668805 @default.
- W2936688088 hasRelatedWork W3096170242 @default.
- W2936688088 hasRelatedWork W3189360127 @default.
- W2936688088 hasRelatedWork W4206568533 @default.
- W2936688088 hasVolume "139" @default.
- W2936688088 isParatext "false" @default.
- W2936688088 isRetracted "false" @default.
- W2936688088 magId "2936688088" @default.
- W2936688088 workType "article" @default.